Pharmacology of GLP-1 RAs Endogenous GLP-1 is secreted from intestinal L-cells following oral nutrient intake
The retinal carotenoids zeaxanthin and lutein scavenge superoxide and hydroxyl radicals: a chemiluminescence and ESR study
Ferrari, R., Merli, E., Cicchitelli, G., Mele, D., Fucili, A., & Ceconi, C
Peak Side Effect Period: Weeks 13 Semaglutide side effects typically reach their peak intensity during the first 13 weeks of treatment
Oral GLP-1 formulations are adding manufacturing complexity in a different dimension: on December 22, 2025, the FDA approved Novo Nordisk's oral Wegovy 25 mg as the first oral GLP-1 therapy for weight loss, bringing with it the manufacturing requirements of oral solid dosage pharmaceutical production at commercial scale, a fundamentally different infrastructure challenge from parenteral peptide API synthesis
Sin embargo, los resultados cientficos son contradictorios